In this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi explain how the guidelines process benefitted from the close collaboration between EASL, EASD, and EASO.
Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
Roger Green conducts 1:1 interviews with Mike Betel, Louise Campbell and Sven Francque while they are at the EASL Congress 2024, discussing key issues related to MASLD
The group, including co-hosts Louise Campbell and Roger Green along with guests Jeff McIntyre and Mike Betel, dives deeper into the care challenges and barriers confronting MASH patient care today.
The conversation shifts to look first at challenges caused by explosion in the use of incretin agonists like GLP-1s to treat obesity and diabetes and second by the opportunities creating by on-site scanning.
Patient advocates Jeff McIntyre (Global Liver Institute) and Mike Betel (Fatty Liver Alliance, Liver Action Network) join Louise Campbell and Roger Green to discuss GLI’s premier MASH patient event, now known as Global Fatty Livery Day.
Hepatologist Tim Jobson, co-founder of Predictive Health Intelligence, joins Louise Campbell and Roger Green to provide an update on PHI’s work and discuss implications for databases, patient recruitment and special population issues.
Hannes Hagstrom and the Surfers consider the ways that increased access to in-office screening will affect clinical care pathways, with special focus on the role of primary care practices.
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.
This final conversation focuses on semaglutide and some of the dual- and triple-increting agonists and then reviews high points of the entire episode.
